Sentence examples for mutation prevalence and from inspiring English sources

To evaluate the mutation prevalence and phenotype in genes involved in the ocular retinoid metabolism.

We have presented estimates of mutation prevalence, and described infections as harbouring two, three or more mutations.

Complex relationships between somatic mutation prevalence and transcription were detected.

Differences in HPV prevalence, p53 mutation prevalence, and pattern of p53 mutations between groups were examined by Fisher's exact test.

The sample size is too small to provide an estimate of full mutation prevalence, and thus the paper is focused on gray zone and premutation alleles.

Targeted capture sequencing of 187 recurrent and pathway-related genes in 160 CRC cases with detailed clinicopathological information was then conducted to evaluate their mutation prevalence and clinical relevance.

4 ASCO criteria and/or prior probability of a BRCA mutation ≥ 30% using Myriad mutation prevalence tables and the Penn II mutation prediction model.

In addition, prior probabilities of carrying a BRCA1 or BRCA2 mutation were determined for each patient using mutation prevalence tables and the Penn II mutation prediction model [ 35- 37].

Among 46,276 subjects (78.3 % Western European ancestry and 3.8 % African ancestry) tested by Myriad Genetics, Inc., BRCA1 and BRCA2 mutation prevalence was 10.2 and 5.7 % in the African ancestry group, respectively versus 6.9 and 5.2 % in populations of Western European ancestry [ 31].

In a study examining BRCA1, BRCA2, CHEK2, and TP53 in US high-risk families (95%% were of European ancestry), 9.6 and 6.5 % of probands were found to be BRCA1 and BRCA2 mutation carriers, and, mutation prevalence increased to 13.2%% (BRCA1) and 7.4%% (BRCA2, CHEK2 and TP53) among patients <49 years old, respectively [ 30].

This included all women with a family history of breast and/or ovarian cancer (190 individuals, 10 BRCandand 17 BRcarriersiers, mutation prevalence 14.2%) and women diagnosed at 35 years or younger with no family history of breast and ovarian cancer (71 individuals, three BRCA1 and four BRCA2 carriers; mutation prevalence, 9.9% (Table 2)).